AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC lowered its stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 64.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 55,472 shares of the medical device company's stock after selling 101,207 shares during the period. Squarepoint Ops LLC owned 0.11% of AtriCure worth $1,695,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Silver Oak Securities Incorporated purchased a new stake in AtriCure during the 4th quarter valued at $220,000. JPMorgan Chase & Co. boosted its stake in AtriCure by 43.1% during the 4th quarter. JPMorgan Chase & Co. now owns 365,183 shares of the medical device company's stock valued at $11,160,000 after purchasing an additional 110,039 shares during the last quarter. Calamos Advisors LLC boosted its stake in AtriCure by 27.9% during the 4th quarter. Calamos Advisors LLC now owns 110,671 shares of the medical device company's stock valued at $3,382,000 after purchasing an additional 24,147 shares during the last quarter. M&T Bank Corp purchased a new stake in AtriCure during the 4th quarter valued at $208,000. Finally, Sei Investments Co. boosted its stake in AtriCure by 6.1% during the 4th quarter. Sei Investments Co. now owns 107,290 shares of the medical device company's stock valued at $3,279,000 after purchasing an additional 6,152 shares during the last quarter. Hedge funds and other institutional investors own 99.11% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on the company. Canaccord Genuity Group cut their target price on AtriCure from $66.00 to $52.00 and set a "buy" rating on the stock in a research note on Friday, March 28th. Needham & Company LLC decreased their target price on AtriCure from $51.00 to $44.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. JMP Securities reissued a "market outperform" rating and set a $60.00 price target on shares of AtriCure in a report on Wednesday, April 30th. Piper Sandler raised their price objective on AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Finally, Wall Street Zen lowered AtriCure from a "buy" rating to a "hold" rating in a research report on Sunday. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $50.67.

Insider Buying and Selling at AtriCure

In related news, Director Karen Prange sold 6,100 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the transaction, the director now owns 17,828 shares of the company's stock, valued at $679,603.36. The trade was a 25.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Vinayak Doraiswamy sold 2,500 shares of the business's stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $33.44, for a total transaction of $83,600.00. Following the completion of the transaction, the insider now directly owns 73,550 shares of the company's stock, valued at $2,459,512. This trade represents a 3.29% decrease in their position. The disclosure for this sale can be found here. Company insiders own 3.50% of the company's stock.

AtriCure Trading Up 2.1%

Shares of NASDAQ:ATRC traded up $0.73 during trading hours on Tuesday, hitting $34.73. 511,013 shares of the company's stock traded hands, compared to its average volume of 649,640. AtriCure, Inc. has a 1 year low of $18.94 and a 1 year high of $43.11. The business has a fifty day moving average price of $32.31 and a 200-day moving average price of $34.67. The firm has a market capitalization of $1.72 billion, a P/E ratio of -36.56 and a beta of 1.57. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62.

AtriCure (NASDAQ:ATRC - Get Free Report) last announced its earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.11. AtriCure had a negative return on equity of 6.80% and a negative net margin of 9.61%. The business had revenue of $123.62 million during the quarter, compared to analyst estimates of $122.92 million. During the same quarter in the previous year, the business earned ($0.28) earnings per share. The company's revenue for the quarter was up 13.5% compared to the same quarter last year. Equities analysts expect that AtriCure, Inc. will post -0.6 earnings per share for the current year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.